Abstract: Roofing shingles are disclosed that are capable of self-adhering to a roof deck or underlayment and/or other roofing shingles and that require few or no mechanical fasteners to remain attached to the roof. By appropriate positioning of sealant lines on the shingle, direct adhesion between the shingle and the roof deck or underlayment and/or other roofing shingles can be achieved. If the shingle is laminated, the layers may be mechanically attached with indentations in the common bond area. The nail zone of the shingle may be visually indicated with fines and/or one or more paint lines. A roofing system comprising a plurality of courses of the shingles is also disclosed.

Abstract: Roofing shingles are disclosed that are capable of self-adhering to a roof deck or underlayment and/or other roofing shingles and that require few or no mechanical fasteners to remain attached to the roof. By appropriate positioning of sealant lines on the shingle, direct adhesion between the shingle and the roof deck or underlayment and/or other roofing shingles can be achieved. If the shingle is laminated, the layers may be mechanically attached with indentations in the common bond area. The nail zone of the shingle may be visually indicated with fines and/or one or more paint lines. A roofing system comprising a plurality of courses of the shingles is also disclosed.

Abstract: A mounting system for an image capture device that includes three pivotably connected arms is disclosed. The first arm includes a first fastener that is lockable and unlockable to allow for connection and disconnection of the image capture device, and a second fastener that is lockable and unlockable to regulate the position of the image capture device relative to the first arm. The mounting system further includes a third fastener that is lockable and unlockable to regulate the relative positioning between the first arm and the second arm, and a fourth fastener that is lockable and unlockable to regulate the relative positioning between the second arm and the third arm. Whereas the first fastener is removable, each of the second, third, and fourth fasteners is captive to (nonremovable from) the mounting system.

Abstract: Methods and systems are provided for manufacturing and implementing solid-state electrolytes (SSEs) for aluminum-based rechargeable batteries and other secondary batteries. In some examples, a SSE composition may include a mixture including urea, sodium chloride, sodium borate, magnesium sulfate, and sodium silicate. In certain examples, the SSE composition may further include carboxymethyl cellulose. In some examples, an aluminum-based secondary battery may be formed by applying a first portion of the SSE composition to an aluminum-based anode via slot-die coating and a second portion of the SSE composition to a cellulose membrane to form a SSE layer, and combining the coated aluminum-based anode, the SSE layer, and a sulfur-based cathode. In certain examples, a current pulse may be applied to the aluminum-based secondary battery to activate in situ solid-electrolyte interphase layers.

Abstract: This invention, in embodiments, relates to a roofing material comprising (a) a coated or covered substrate and (b) a single sealant applied to a surface of the coated or covered substrate, with the single sealant being free of asphalt. The single sealant exhibits a minimum activation temperature (° C.) (tan ?>1) from ?10° C. to 0° C. The single sealant is configured to adhere the roofing material to at least one of (i) an underlying roofing material, (ii) an overlying roofing material, and (iii) a roofing deck substrate.

Abstract: Examples described herein relate to offload reliable transport management to a network interface device and store packets to be resent, based on received packet receipt acknowledgements (ACKs), into one or more kernel space queues that are also accessible in user space.

Abstract: Provided herein are methods of treating eye disorders by administering an anti-VEGF antibody and/or conjugate to a subject having an eye disorder. The anti-VEGF antibody of the present disclosure may be an anti-VEGF antibody conjugate that includes a polymeric moiety that extends the half-life/effectiveness/properties of the antibody when administered to a subject. A method of the present disclosure includes administering one or more doses of an anti-VEGF antibody conjugate to a subject (e.g., human or other mammalian patient) in need of treating an eye disorder, where the anti-VEGF antibody conjugate may be administered less frequently than a standard anti-VEGF therapy to treat the eye disorder.

Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.

Abstract: Techniques for creating and using error tables to track errors associated with a base table are described. A command to perform an operation on a base table stored in a network-based data system can be received and executed, causing at least one error. At least one error record corresponding to the at least one error can be inputted into an error table, which is nested with the base table. Contextual information can be added to the at least one error record.

Abstract: Provided herein are methods of treating eye disorders by administering an anti-VEGF antibody and/or conjugate to a subject having an eye disorder. The anti-VEGF antibody of the present disclosure may be an anti-VEGF antibody conjugate that includes a polymeric moiety that extends the half-life/effectiveness/properties of the antibody when administered to a subject. A method of the present disclosure includes administering one or more doses of an anti-VEGF antibody conjugate to a subject (e.g., human or other mammalian patient) in need of treating an eye disorder, where the anti-VEGF antibody conjugate may be administered less frequently than a standard anti-VEGF therapy to treat the eye disorder.

Abstract: A method for producing a metal structure comprising a porous inter-dendritic matrix defining a network of dendritic channels, the method comprising the steps of: preparing an alloy melt comprising a metal element and at least one alloying element, cooling the alloy melt to a solid alloy, wherein the cooling promotes formation of a network of dendrites rich in the at least one alloying element within an inter-dendritic matrix rich in the metal, dealloying the solid alloy to remove alloying element from the dendrites and the inter-dendritic matrix to obtain the metal structure.

Abstract: An improved magnesium-based alloy for wrought applications is disclosed, including a method of fabricating alloy sheet from said alloy. The improved magnesium-based alloy consists of: 0.5 to 4.0% by weight zinc; 0.02 to 0.70% by weight a rare earth element, or mixture of the same including gadolinium; and incidental impurities. The rare earth element in some embodiments may be yttrium and/or gadolinium. In some embodiments the magnesium-based alloy may also consist of a grain refiner and in some embodiments the grain refiner may be zirconium. In combination, the inclusion of zinc and a rare earth element, into the magnesium alloy may have enhanced capacity for rolling workability, deep drawing at low temperatures and stretch formability at room temperature. The improved alloy may also exhibit increased tensile strength and formability while evincing a reduced tendency for tearing during preparation.

Abstract: The present disclosure provides an automated bioprocessing device, which may comprises a processing machine, one or more removable washing cartridges. The removable washing cartridge may comprise a shell, a sample holder, a washing basin, a waste container, a reagent container, a rotation mechanism, and a poking mechanism. The processing machine may comprise a motor, which may provide power to the inserted removable washing cartridge.

Abstract: The present disclosure is directed to peptide-based compounds, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present disclosure may inhibit neurotransmitter release and muscle contraction as a treatment for wrinkles. The compounds of the disclosure may be used for pathological neuronal exocytosis-mediated cosmetic and/or therapeutic purposes.

Abstract: The present disclosure provides an automated bioprocessing device, which may comprises a processing machine, one or more removable washing cartridges. The removable washing cartridge may comprise a shell, a sample holder, a washing basin, a waste container, a reagent container, a rotation mechanism, and a poking mechanism. The processing machine may comprise a motor, which may provide power to the inserted removable washing cartridge.

Abstract: The present invention provides devices, apparatuses and methods for automated processing of biological samples. This invention provides automated devices and automated methods of sequentially treating a biological sample with processing fluids in more than one washing basin. In some embodiments, the invention provides automated devices and automated methods of western blot processing. In some embodiments, the invention provides automated devices and automated methods of Southern blot processing. In some embodiments, the invention provides automated devices and automated methods of northern blot processing. In some embodiments, the invention provides automated devices and automated methods of staining biomolecules on solid supports. In some embodiments, the invention provides automated devices and automated methods of nucleic acid separation and isolation.

Abstract: The present disclosure is directed to peptide-based compounds, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present disclosure may inhibit neurotransmitter release and muscle contraction as a treatment for wrinkles. The compounds of the disclosure may be used for pathological neuronal exocytosis-mediated cosmetic and/or therapeutic purposes.

Abstract: An improved magnesium-based alloy for wrought applications is disclosed, including a method of fabricating alloy sheet from said alloy. The improved magnesium-based alloy consists of: 0.5 to 4.0% by weight zinc; 0.02 to 0.70% by weight a rare earth element, or mixture of the same including gadolinium; and incidental impurities. The rare earth clement in some embodiments may be yttrium and/or gadolinium. In some embodiments the magnesium-based alloy may also consist of a grain refiner and in some embodiments the grain refiner may be zirconium. In combination, the inclusion of zinc and a rare earth element, into the magnesium alloy may have enhanced capacity for rolling workability, deep drawing at low temperatures and stretch formability at room temperature. The improved alloy may also exhibit increased tensile strength and formability while evincing a reduced tendency for tearing during preparation.

Abstract: The present invention provides devices, apparatuses and methods for automated processing of biological samples. This invention provides automated devices and automated methods of sequentially treating a biological sample with processing fluids in more than one washing basin. In some embodiments, the invention provides automated devices and automated methods of western blot processing. In some embodiments, the invention provides automated devices and automated methods of Southern blot processing. In some embodiments, the invention provides automated devices and automated methods of northern blot processing. In some embodiments, the invention provides automated devices and automated methods of staining biomolecules on solid supports. In some embodiments, the invention provides automated devices and automated methods of nucleic acid separation and isolation.